STOCK TITAN

Ultragenyx (RARE) EVP Harris receives RSU and option grants in equity award

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Ultragenyx Pharmaceutical EVP & Chief Commercial Officer Erik Harris received new equity awards. He was granted 28,895 shares of common stock in the form of restricted stock units (RSUs) under the company’s 2023 Incentive Plan, bringing his direct common stock holdings to 118,410 shares.

He also received a stock option for 49,960 shares of common stock at an exercise price of $24.52 per share, expiring on April 16, 2036. The RSUs vest in four equal annual installments, while the option vests 25% on the first anniversary of the grant date and 1/48 monthly thereafter.

Positive

  • None.

Negative

  • None.
Insider Harris Erik
Role EVP & Chief Commercial Officer
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 49,960 $0.00 --
Grant/Award Common Stock 28,895 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 49,960 shares (Direct, null); Common Stock — 118,410 shares (Direct, null)
Footnotes (1)
  1. Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
RSU grant size 28,895 shares Restricted Stock Units granted April 16 under 2023 Incentive Plan
Post-grant common stock holdings 118,410 shares Direct common stock held after RSU award
Stock option grant size 49,960 shares New stock option covering common stock
Option exercise price $24.52 per share Conversion or exercise price for 49,960-share option
Option expiration April 16, 2036 Expiration date of the granted stock option
RSU vesting schedule 25% annually over 4 years RSUs vest 1/4 on each grant anniversary
Option vesting schedule 25% at 1 year, then 1/48 monthly From option anniversary date until fully vested
Restricted Stock Units ("RSUs") financial
"Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2023 Incentive Plan financial
"Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan."
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with underlying security title Common Stock."
Option Anniversary Date financial
"On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest;"
vesting conditions financial
"shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."
Vesting conditions are the rules that determine when someone earning company stock or stock options actually gains the right to keep or sell them, typically based on staying with the company for a set time or meeting performance targets. Think of it like keys that unlock gradually — some unlock by calendar date, others only after agreed milestones. Investors care because vesting shapes management incentives, the timing of share sales, and the number of shares that can enter the market, which can affect a company's valuation and ownership mix.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Harris Erik

(Last)(First)(Middle)
60 LEVERONI COURT

(Street)
NOVATO CALIFORNIA 94949

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Ultragenyx Pharmaceutical Inc. [ RARE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP & Chief Commercial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/16/2026A28,895(1)A$0118,410(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$24.5204/16/2026A49,960 (3)04/16/2036Common Stock49,960$049,960D
Explanation of Responses:
1. Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
2. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
3. On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
/s/ Karah Parschauer, attorney-in-fact04/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Ultragenyx (RARE) EVP Erik Harris receive?

Erik Harris received 28,895 restricted stock units and a stock option for 49,960 shares. The option has a $24.52 exercise price and expires in 2036, representing compensation-based equity rather than an open-market stock purchase or sale.

How do Erik Harris’s new RSUs at Ultragenyx (RARE) vest?

The 28,895 RSUs vest in four equal annual installments. One-quarter of the underlying shares vests on each anniversary of the April 16 grant date, so the award becomes fully vested on the fourth anniversary, subject to the plan’s conditions.

What are the terms of Erik Harris’s new Ultragenyx (RARE) stock option?

The stock option covers 49,960 shares of common stock at a $24.52 exercise price. Twenty-five percent of the shares vest one year after grant, and 1/48 of the original amount vests each month thereafter until the April 16, 2036 expiration.

How many Ultragenyx (RARE) shares does Erik Harris hold after this Form 4?

After the RSU grant, Erik Harris directly holds 118,410 shares of Ultragenyx common stock. This figure includes previously reported RSU-based common shares that remain subject to vesting conditions under the company’s incentive plan.

Are Erik Harris’s Ultragenyx (RARE) transactions open-market buys or compensation?

These transactions are compensation-related awards, not open-market trades. Both the 28,895 RSUs and the 49,960-share stock option were granted under Ultragenyx’s 2023 Incentive Plan, with no purchase price paid for the awards at grant.